troglitazone has been researched along with pioglitazone in 198 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 29 (14.65) | 18.2507 |
| 2000's | 124 (62.63) | 29.6817 |
| 2010's | 40 (20.20) | 24.3611 |
| 2020's | 5 (2.53) | 2.80 |
| Authors | Studies |
|---|---|
| Cantello, BC; Cawthorne, MA; Cottam, GP; Duff, PT; Haigh, D; Hindley, RM; Lister, CA; Smith, SA; Thurlby, PL | 1 |
| Buckle, DR; Cantello, BC; Chapman, H; Clapham, JC; Coyle, PJ; Haigh, D; Hindley, RM; Holder, JC; Kallender, H; Latter, AJ; Lawrie, KW; Mossakowska, D; Murphy, GJ; Roxbee Cox, L; Smith, SA; Young, PW | 1 |
| Iwao, M; Onogi, S; Shibata, T; Shinkai, H; Tanaka, M; Uchida, I; Wakitani, K | 1 |
| Blanchard, SG; Brackeen, MF; Brown, KK; Cobb, JE; Collins, JL; Harrington, WW; Hashim, MA; Henke, BR; Hull-Ryde, EA; Kaldor, I; Kliewer, SA; Lake, DH; Leesnitzer, LM; Lehmann, JM; Lenhard, JM; Miller, JF; Mook, RA; Noble, SA; Oliver, W; Orband-Miller, LA; Parks, DJ; Plunket, KD; Szewczyk, JR; Willson, TM | 1 |
| Awano, K; Kinoshita, S; Maeda, T; Miyachi, H; Murakami, K; Nomura, M; Satoh, H; Tsunoda, M | 1 |
| Adkison, KK; Blanchard, SG; Henke, BR; Leesnitzer, LM; Mook, RA; Plunket, KD; Ray, JA; Roberson, C; Unwalla, R; Willson, TM | 1 |
| Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM | 1 |
| Andersen, AS; Brand, CL; Bury, PS; Fleckner, J; Jeppesen, L; Lehmann, SV; Mogensen, JP; Mortensen, SB; Panajotova, V; Pettersson, I; Polivka, Z; Rasmussen, HB; Sauerberg, P; Sindelar, K; Sturis, J; Svensson, LA; Wassermann, K; Wöldike, HF; Wulff, EM; Ynddal, L | 1 |
| Goto, A; Nakajima, M; Nezu, J; Nozawa, T; Sugiura, S; Tamai, I; Tsuji, A; Yokoi, T | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Bhattarai, BR; Cho, H; Ham, SW; Han, IO; Hwang, JS; Kafle, B; Kang, JS; Khadka, D; Lee, SM; Park, H | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Carroll, RT; Darvesh, AS; Funk, MO; Geldenhuys, WJ; Van der Schyf, CJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Aldeco, M; Binda, C; Edmondson, DE; Geldenhuys, WJ; Mattevi, A; Tortorici, M | 1 |
| Lin, HR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Dhangar, K; Jagtap, R; Karpoormath, R; Noolvi, M; Patel, H; Rane, RA; Shaikh, MS; Sonawane, Y; Surana, S; Thapliyal, N | 1 |
| Bahia, MS; Chadha, N; Kaur, M; Silakari, O | 1 |
| Barnard, A; Cao, J; Deng, Y; Eidenschenk, C; Everett, C; Fauber, BP; Ganguli, A; Gobbi, A; Hawkins, J; Johnson, AR; La, H; Norman, M; Ouyang, W; Robarge, K; Salmon, G; Summerhill, S; Tang, W; Wong, H; Zhou, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Adams, WJ; Artman, GD; Colca, JR; Gadwood, RC; Kletzien, RF; Larsen, SD; Lee, PH; McDonald, WG; Parker, TT; Tanis, SP; Zeller, JB | 1 |
| Ahn, S; An, S; Choi, H; Jeong, LS; Ko, H; Noh, M; Pyo, JJ; Shin, JC; Yu, J | 1 |
| Norman, BH | 1 |
| Aamir Javed, M; Ikram, M; Jadoon, R; Mahnashi, MH; Rashid, U; Sadiq, A; Saeed Jan, M; Shahid, M | 1 |
| Amri, EZ; Gaillard, D; Grimaldi, PA; Inadera, H; Staccini, L; Teboul, L | 1 |
| Daimon, M; Eguchi, H; Igarashi, M; Matsumoto, M; Sasaki, H; Sekikawa, A; Tominaga, M; Yamatani, K | 1 |
| Umeda, F | 1 |
| Lambe, KG; Tugwood, JD | 1 |
| Fulgencio, JP; Girard, J; Kohl, C; Pégorier, JP | 1 |
| Kawamori, R; Yoshii, H | 1 |
| Connell, J; Petrie, J; Small, M | 1 |
| Inoue, I; Katayama, S; Komoda, T; Miyazaki, T; Negishi, K; Sonoda, M; Takahashi, K | 1 |
| Peraldi, P; Spiegelman, BM; Xu, M | 1 |
| Hirose, T; Kasayama, S; Kishimoto, T; Kurebayashi, S; Miyashita, Y | 1 |
| Akatsuka, H; Arakawa, K; Homma, K; Iijima, I; Inamasu, M; Kawanami, S; Matsumoto, M; Okumura, K; Ozeki, M; Saiga, Y; Watanabe, A; Yasuda, K | 1 |
| Kitaoka, H | 2 |
| Hari, J | 1 |
| Breider, MA; Gralinski, MR; Rowse, PE | 1 |
| Ishizawa, M; Ishizuka, T; Itaya, S; Kajita, K; Kanoh, Y; Kimura, M; Miura, A; Muto, N; Wada, H; Yasuda, K | 1 |
| Ikeda, S; Watanabe, T | 1 |
| Hara, M; Hashimoto, N; Hashimoto, Y; Isoo, N; Kimura, S; Maekawa, H; Satoh, H; Togo, M; Tsukamoto, K; Watanabe, T | 1 |
| Matsui, K; Nagao, K; Shibata, T; Shinkai, H; Wakitani, K; Yonemori, F | 1 |
| Endo, Y; Fujita, T; Kato, K; Midorikawa, S; Mizuno, K; Sato, W; Satoh, H; Tsukamoto, K; Watanabe, T; Yamada, D | 1 |
| Andres, E; Blicklé, JF; Brogard, JM; Neyrolles, N | 1 |
| Asano, M; Chisaki, K; Imuta, H; Iwasawa, K; Morita, T; Nakajima, T; Nakamura, F; Okuda, Y; Omata, M; Yamada, N | 1 |
| Gonoi, T; Inagaki, N; Ishida, H; Seino, S; Seino, Y; Sunaga, Y; Yamada, Y | 1 |
| Fujita, T; Fukumoto, S; Miyamoto, M; Okazaki, R; Takeuchi, Y; Tanaka, K; Toriumi, M | 1 |
| Kuritzky, L; Quillen, DM; Samraj, GP | 1 |
| Nakajima, M; Shimada, N; Suzuki, M; Tane, K; Yamazaki, H; Yokoi, T | 1 |
| Shimizu, N | 1 |
| Hirayama, R; Kurosaki, E; Nakano, R; Shibasaki, M; Shikama, H; Shimaya, A | 1 |
| Daimon, M; Kato, T; Kimura, M; Manaka, H; Sasaki, H; Tominaga, M | 1 |
| Fukumoto, S; Hosoi, M; Koyama, H; Morii, H; Nishizawa, Y; Tanaka, S; Yamakawa, K | 1 |
| Brown, MN | 1 |
| Kadowaki, T | 1 |
| King, AB | 1 |
| Reddy, SS | 1 |
| Haneda, M; Isshiki, K; Kikkawa, R; Koya, D; Maeda, S; Sugimoto, T | 1 |
| Krische, D | 1 |
| Hisatome, I; Ogino, K; Shigemasa, C; Shimoyama, M; Uchida, K | 1 |
| Bailey, CJ; Krentz, AJ; Melander, A | 1 |
| Kitahara, M; Naitoh, T; Tsuruzoe, N | 1 |
| Barbehenn, E; Lurie, P; Sasich, LD; Wolfe, SM | 1 |
| Naruse, M; Tago, K; Takagi, S; Takano, K; Tanabe, A; Yoshimoto, T | 1 |
| Stiefelhagen, P | 1 |
| Filz, HP | 1 |
| Hiwada, K; Kitami, Y; Nakamura, M; Okura, T; Takata, Y; Watanabe, S | 1 |
| Banba, N; Hattori, Y; Hishinuma, A; Kakishita, H; Kasai, K; Matsumura, M; Motohashi, S; Sato, N | 1 |
| Kimura, H; Momose, Y; Moriyama, S; Odaka, H; Sakamoto, J; Sawada, H; Sugiyama, Y | 1 |
| Chen, L; Cohen, SE; Kahn, CR | 1 |
| Hirosumi, J; Kojo, H; Mutoh, S; Notsu, Y; Suzuki, A; Yasuno, T | 1 |
| Henry, RR; Mudaliar, S | 1 |
| Albrektsen, T; Fleckner, J | 1 |
| Arakawa, Y; Kimoto, K; Nishijima, C | 1 |
| Abe, T; Nagai, Y; Nomura, G | 1 |
| Banerji, MA; Lebovitz, HE | 1 |
| Arlt, W; Auchus, RJ; Miller, WL | 1 |
| Ito, T; Morita, H; Nakamura, H; Ohishi, H; Oki, Y; Suzuki, S | 1 |
| Janka, HU | 1 |
| Amin, RD; Dilzer, S; Gagliano, K; Kuznetsova, O; Lasseter, KC; Liu, L; Musser, B; Prueksaritanont, T; Roadcap, BA; Rogers, JD; Vega, JM; Zhao, J | 1 |
| Arima, S; Ikeda, Y; Ito, S; Kudo, M; Sato, K; Sugawara, A; Takeuchi, K; Taniyama, Y; Uruno, A | 1 |
| Gale, EA | 1 |
| Abe, I; Eto, K; Fujishima, M; Nakamura, Y; Ohya, Y | 1 |
| Blicklé, JF | 1 |
| Chlenski, A; Hattori, K; Hayashi, Y; Kita, A; Nakashiro, KI; Oyasu, R; Reddy, JK; Tamatani, T; Usuda, N | 1 |
| Csermely, P; Jermendy, G | 1 |
| Chun, TH; Doi, K; Fukunaga, Y; Hosoda, K; Inoue, M; Itoh, H; Kook, H; Masatsugu, K; Nakao, K; Saito, T; Sawada, N; Tanaka, T; Ueda, M; Yamashita, J | 1 |
| Ando, K; Chiba, Y; Fujita, T; Ogita, T | 1 |
| Algenstaedt, P; Hamann, A | 1 |
| Jazet, IM; Meinders, AE | 1 |
| Inoue, K; Kawahito, Y; Kohno, M; Sano, H; Tsubouchi, Y; Yoshikawa, T; Yoshimura, R | 1 |
| Haneda, M; Kikkawa, R; Koya, D | 1 |
| Ichiki, T; Iino, N; Takeda, K; Takeshita, A; Tokunou, T | 1 |
| Iwata, M; Kobayashi, M | 1 |
| Kitamura, R; Tanaka, Y | 1 |
| Scheen, AJ | 1 |
| Nakajima, M; Yamamoto, Y; Yamazaki, H; Yokoi, T | 1 |
| Asakawa, M; Hasegawa, H; Kadowaki, T; Komuro, I; Kubota, N; Masuda, Y; Nagai, T; Saito, T; Takano, H; Uozumi, H | 1 |
| Khan, MA; St Peter, JV; Xue, JL | 1 |
| Abe, T; Ishibashi, S; Ishikawa, S; Kawakami, A; Kusaka, I; Nagasaka, S; Nakamura, T; Saito, T | 1 |
| Iida, KT; Kawakami, Y; Okuda, Y; Shimano, H; Sone, H; Suzuki, H; Toyoshima, H; Yamada, N | 1 |
| Goto, K; Irukayama-Tomobe, Y; Miyauchi, T; Ogata, T; Sakai, S; Yamaguchi, I | 1 |
| Hase, T; Kawahito, Y; Mitsuhashi, M; Nakatani, T; Sano, H; Segawa, Y; Wada, S; Yoshimura, R | 1 |
| Yamanouchi, T | 1 |
| Hosaka, D; Imai, Y; Kawazu, S; Ohmura, E | 1 |
| Aburatani, H; Blumberg, RS; Kadowaki, T; Matsuhashi, N; Nagai, R; Nakajima, A; Saubermann, LJ; Terauchi, Y; Wada, K; Zhao, S | 1 |
| Kaplowitz, N; Lewis, JH; Watkins, PB | 1 |
| Fujisawa, N; Ishimine, S; Kadowaki, T; Kawamori, T; Matsuhashi, N; Nakagama, H; Nakajima, A; Ochiai, M; Osawa, E; Sekihara, H; Wada, K | 1 |
| Iida, KT; Iwama, Y; Kamata, K; Kawakami, Y; Mokuno, H; Shimada, K; Shimano, H; Sone, H; Suzuki, M; Toyoshima, H; Watanabe, Y; Yamada, N | 1 |
| Bruun, JM; He, G; Lihn, AS; Pedersen, SB; Richelsen, B | 1 |
| Carter, L; Ciaraldi, TP; Henry, RR; Mudaliar, SR; Reehman, N; Wilmsen, HM | 1 |
| Moses, R | 1 |
| Bruemmer, D; de Dios, ST; Dilley, RJ; Ivey, ME; Jennings, GL; Law, RE; Little, PJ | 1 |
| Chandramouli, J; Tolman, KG | 1 |
| Flight, IH; Lord, JM; Norman, RJ | 1 |
| Game, BA; Huang, Y; Lopes-Virella, MF; Xu, M | 1 |
| Begum, NM; Hamakawa, H; Kawamata, H; Nakashiro, K; Sato, M; Shintani, S; Uchida, D | 1 |
| Haraguchi, K; Onaya, T; Shimura, H | 1 |
| Narce, M; Poisson, JP | 1 |
| Asnani, S; DeSouza, C; Fonseca, V; Gilling, L; Suwattee, P | 1 |
| Bode, C; Ernst, S; Leugers, A; Lohrmann, J; Nordt, TK; Sobel, BE; Zirlik, A | 1 |
| Hayashi, K; Homma, K; Kanda, T; Saruta, T; Takamatsu, I; Tatematsu, S; Wakino, S; Yoshioka, K | 1 |
| Naito, Y; Yoshikawa, T | 1 |
| Adachi, T; Hara, H; Inoue, M; Suzuki, S | 1 |
| Guo, YT; Leng, XS; Li, T; Lin, XH; Zhao, JM | 1 |
| Chen, J; Chen, Q; Jiang, H; Shen, J; Shen, X; Sun, T | 1 |
| Camacho, IE; De Strooper, B; Dominguez, D; Merchiers, P; Serneels, L; Spittaels, K | 1 |
| Gamboa, JL; Landreth, GE; Lust, WD; Sundararajan, S; Victor, NA; Wanderi, EW | 1 |
| Arai, H; Chun, TH; Doi, K; Fukunaga, Y; Inoue, M; Itoh, H; Masatsugu, K; Nakao, K; Saito, T; Sakaguchi, S; Sawada, N; Tanaka, T; Yamashita, J | 1 |
| Guo, YT; Leng, XS; Li, T; Lin, XH; Zhao, JM; Zhu, JY | 1 |
| Fugate, SE; Stout, DL | 1 |
| Babaya, N; Fujisawa, T; Ikegami, H; Inoue, K; Itoi-Babaya, M; Kawabata, Y; Nishino, M; Nojima, K; Ogihara, T; Ono, M; Taniguchi, H | 1 |
| Anthwal, S; Arenberg, DA; Keshamouni, VG; Newstead, MJ; Reddy, RC; Standiford, TJ | 1 |
| Brougham, L; Chan, K; Duczak, N; Elliot, M; Lim, HK; Patel, K | 1 |
| Artwohl, M; Baumgartner-Parzer, SM; Freudenthaler, A; Fürnsinn, C; Hölzenbein, T; Huttary, N; Waldhäusl, WK | 1 |
| Guan, YF; Guo, YL; Shi, CJ; Wu, JP; Xin, DQ; Yang, FG; Zhang, ZW | 1 |
| Fröhlich, E; Machicao, F; Wahl, R | 1 |
| Bouaboula, M; Casellas, P; Fajas, L; Hilairet, S; Le Fur, G; Marchand, J | 1 |
| Buechler, C; Kirchner, S; Laberer, S; Neumeier, M; Schäffler, A; Schölmerich, J; Weigert, J; Weiss, T | 1 |
| Freston, JW; Schlichting, CL; Slavin, DE | 1 |
| Bultemeier, NC; Hartung, DM; Haxby, DG; Touchette, DR | 1 |
| El Beltagy, K; Honda, K; Ishiko, O; Misugi, T; Ozaki, K; Tokuyama, O | 1 |
| Nilsson, PM; Sarafidis, PA | 1 |
| Bakris, GL; Sarafidis, PA | 1 |
| Alvarez-Sanchez, R; Hartung, T; Montavon, F; Pähler, A | 1 |
| Chayama, K; Hyogo, H; Kobuke, T; Tazuma, S | 1 |
| Blann, E; Dial, S; Dragan, YP; Guo, L; Muskhelishvili, L; Schroth, G; Shi, L; Sun, Y; Zhang, L | 1 |
| Campbell, IW; Mariz, S | 1 |
| Friday, E; Nissim, I; Oliver, R; Turturro, F; Welbourne, T | 1 |
| Hruz, PW; Rudnick, DA; Shikapwashya, O; Tu, S; Turmelle, YP; Yan, Q | 1 |
| Bertin, I; Dauça, M; Domenjoud, L; Fiatte, C; Huin, C; Lesuffleur, T; Plénat, F; Pluvinet, A; Schohn, H; Touche, N | 1 |
| Hampton, T | 1 |
| Krentz, AJ | 1 |
| Au, AL; Chan, SW; Kwan, YW; Lam, TY; Leung, GP; Ngai, SM; Seto, SW | 1 |
| Giaginis, C; Theocharis, S; Tsantili-Kakoulidou, A | 1 |
| Chalasani, N; Khashab, M | 1 |
| Buchanan, TA; Goico, J; Hodis, HN; Kawakubo, M; Kjos, SL; Liu, CH; Liu, CR; Marroquin, A; Ochoa, C; Peters, RK; Xiang, AH | 1 |
| Kanazawa, A; Kawamori, R | 1 |
| Chen, J; Gangireddy, S; Kalemkerian, GP; Keshamouni, VG; Reddy, K; Reddy, RC; Srirangam, A; Standiford, TJ | 1 |
| Grönberg, G; Hansen, SH; Jurva, U; Madsen, KG; Olsen, J; Skonberg, C | 1 |
| Bianco, AC; Grozovsky, R; Huang, SA; Kim, BW; Mulcahey, MA; Patti, ME; Ribich, S; Rosene, ML | 1 |
| Deng, R; Kaimal, R; King, R; Song, X; Yan, B | 1 |
| Karpushev, AV; Levchenko, V; Pavlov, TS; Staruschenko, A; Vandewalle, A | 1 |
| Liao, K; Xiao, Y; Yao, W; Yuan, T | 1 |
| Andreesen, R; Gottfried, E; Hartmannsgruber, G; Kreutz, M; Kunz-Schughart, LA; Peter, K; Peuker, A; Reichle, A; Rogenhofer, S; Waibel, H; Wehrstein, M | 1 |
| Liao, X; Wang, Y; Wong, CW | 1 |
| Al-Alem, L; Curry, TE; Kilgore, MW; Southard, RC | 1 |
| Arnold, LL; Cohen, SM; Kakiuchi-Kiyota, S; Pennington, KL; Suzuki, S; Yokohira, M | 1 |
| Andersen, OS; Greathouse, DV; Hemmings, HC; Herold, KF; Rusinova, R; Sanford, RL | 1 |
| Amacher, DE; Boucher, GG; Francone, O; Kerlin, RL; Morton, D; Pettersen, JC; Pruimboom-Brees, IM; Will, Y | 1 |
| Drews, G; Düfer, M; Edalat, A; Krippeit-Drews, P; Noack, K | 1 |
| Chan, DS; Chan, EC; Chui, WK; Ho, HK; Lee, CY; New, LS; Saha, S; Wong, W; Yap, CW | 1 |
| Cheng, YC; Chiang, MC; Lin, KH; Yen, CH | 1 |
| Bucolo, C; Drago, F; Salomone, S; Siarkos, I; Sinagra, T; Tamburella, A; Urso, V | 1 |
| Cho, DH; Han, SH; Jo, I; Kwon, KJ; Lee, EJ; Park, JH; Shin, CY; Song, KH | 1 |
| Furumura, M; Hashimoto, T; Karashima, T; Numata, S; Ohyama, B; Tanida, N; Teye, K; Yan, Y | 1 |
| Abete, P; Bellia, A; Cacciatore, F; Capuani, B; Dave, KR; De Marchis, ML; Della-Morte, D; Donadel, G; Dong, C; Ferroni, P; Fogliame, G; Guadagni, F; Lauro, D; Pacifici, F; Palmirotta, R; Pastore, D; Pileggi, A; Rehni, AK; Ricordi, C; Roselli, M; Rundek, T; Sbraccia, P | 1 |
| Ding, RG; Fan, X; Hu, D; Li, ZJ; Liu, Y; Wang, QJ; Wu, CQ | 1 |
| Geng, B; He, J; Jiang, H; Kuang, J; Liu, Q; Mo, L; Xu, C; Xu, G | 1 |
| Kawaguchi, K; Kawase, R; Koiwa, J; Miyazaki, T; Murakami, S; Nishimura, Y; Nomoto, T; Sasagawa, S; Shintou, T; Tanaka, T; Yuge, M | 1 |
| Jiang, M; Li, X | 1 |
| Allen, KM; Coughlan, KA; Mahmood, FN; Ruderman, NB; Saha, AK; Valentine, RJ | 1 |
| Hayes, A; Kato, R; Mak, A; Uetrecht, J; Weston, K | 1 |
| Chang, JH; Jaochico, A; Liu, N; Plise, E; Sangaraju, D | 1 |
| Deacon, CF; Elahi, D; Gupta, D; Holst, JJ; Pratley, RE; Sideleva, O; Tharp, WG | 1 |
| Aparicio-Prat, E; Lanz, TA; Moccia, R; Quan, J; Sholder, G; Stanton, R; Xi, HS | 1 |
42 review(s) available for troglitazone and pioglitazone
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2000 |
Thiazolidine-2,4-dione derivatives: programmed chemical weapons for key protein targets of various pathological conditions.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Antidiuretic Agents; Antineoplastic Agents; Antioxidants; Drug Design; Humans; Molecular Targeted Therapy; Structure-Activity Relationship; Thiazolidinediones | 2015 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.
Topics: Animals; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Drug Discovery; Drug Evaluation, Preclinical; Hepatocytes; Humans; Liver; Mitochondria, Liver; Pharmaceutical Preparations; Risk Assessment; Tissue Distribution | 2020 |
Potential role of thiazolidinediones in older diabetic patients.
Topics: Aged; Aging; Animals; Benzopyrans; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Resistance; Japan; Mice; Pioglitazone; Randomized Controlled Trials as Topic; Rats; Thiazoles; Thiazolidinediones; Troglitazone | 1995 |
[Drug therapy in subjects with impaired glucose tolerance].
Topics: Acarbose; Biguanides; Chromans; Diabetes Mellitus, Type 2; Glucose Intolerance; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Metformin; Pioglitazone; Risk Factors; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Trisaccharides; Troglitazone | 1996 |
[Alpha-glucosidase inhibitor and insulin sensitizer combination therapy in NIDDM].
Topics: Acarbose; Animals; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin Resistance; Pioglitazone; Thiazoles; Thiazolidinediones; Trisaccharides; Troglitazone | 1997 |
[Combination therapy of insulin sensitizer and sulfonylurea].
Topics: Blood Glucose; Chromans; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pioglitazone; Protein Precursors; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
[Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs].
Topics: Administration, Oral; Chromans; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exercise; Fenfluramine; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lactones; Lipase; Metformin; Orlistat; Peroxisome Proliferators; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Improving management of type 2 diabetes mellitus: 5. Thiazolidinediones.
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Combinations; Drug Interactions; Drug Monitoring; Humans; Hypoglycemic Agents; Liver Function Tests; Patient Selection; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Failure; Troglitazone | 2000 |
[Proper usage of thiazolidinediones].
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Liver Failure, Acute; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
The thiazolidinediones or "glitazones" a treatment option for type 2 diabetes mellitus.
Topics: Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Synergism; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2000 |
[Hypoglycemic agents to improve insulin resistance].
Topics: Adipocytes; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Hyperglycemia; Hyperinsulinism; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
The glitazones: proceed with caution.
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Evaluation; Humans; Hypoglycemic Agents; Liver; Pioglitazone; Prognosis; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Troglitazone; Weight Gain | 2000 |
[Insulin-sensitizing agents and hypertension].
Topics: Animals; Chromans; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2001 |
Insulin resistance and its treatment by thiazolidinediones.
Topics: Adipose Tissue; Binding Sites; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dimerization; Drug Interactions; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Male; Models, Biological; Muscle, Smooth; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sex Factors; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
[Glitazones. Profile of a new class of substances].
Topics: Albuminuria; Animals; Anticholesteremic Agents; Chromans; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Germany; Humans; Hypoglycemic Agents; Isoenzymes; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States | 2001 |
Lessons from the glitazones: a story of drug development.
Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Drug Approval; Drug Therapy, Combination; Europe; Humans; Hypoglycemic Agents; Liver Failure; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States | 2001 |
[Thiazolidinediones: clinical data and perspectives].
Topics: Animals; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
[Thiazolidinediones--a new class of oral antidiabetic drugs].
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
[Glitazone--a new class of drugs for the treatment of type 2 diabetes].
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
[The thiazolidinedione derivates: a new class of oral blood glucose lowering agents].
Topics: Administration, Oral; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
[Evaluation of thiazolidinedione derivative drugs for safety].
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Edema; Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
[Clinical usefulness of combination treatment with thiazolidinedione and insulin].
Topics: Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Multicenter Studies as Topic; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Hepatotoxicity with thiazolidinediones: is it a class effect?
Topics: Aged; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
[Insulin sensitizer drugs--review].
Topics: Adipose Tissue; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
[Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes].
Topics: Acarbose; Animals; Biguanides; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin Resistance; Pioglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
[Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].
Topics: Blood Glucose; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Repaglinide in combination therapy.
Topics: Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Pioglitazone; Piperidines; Postprandial Period; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2002 |
Hepatotoxicity of the thiazolidinediones.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Humans; Hypoglycemic Agents; Liver Failure, Acute; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States; United States Food and Drug Administration | 2003 |
Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.
Topics: Anovulation; Chromans; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Ovulation Induction; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Effects of the thiazolidinediones on cardiovascular risk factors.
Topics: Cardiovascular Diseases; Chromans; Clinical Trials as Topic; Endothelium, Vascular; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones; Troglitazone | 2002 |
Thiazolidinediones: a new class of drugs for the therapy of ischemia-reperfusion injury.
Topics: Animals; Anti-Inflammatory Agents; Chromans; Humans; Ligands; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Reperfusion Injury; Rosiglitazone; Thiazolidinediones; Transcription Factors; Troglitazone | 2004 |
Thiazolidinediones for treatment of polycystic ovary syndrome.
Topics: Adult; Chromans; Clinical Trials as Topic; Clomiphene; Contraceptives, Oral; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Ovulation; Pioglitazone; Polycystic Ovary Syndrome; Thiazolidinediones; Troglitazone | 2005 |
The effects of thiazolidinediones on blood pressure levels - a systematic review.
Topics: Blood Pressure; Chromans; Humans; Hypertension; MEDLINE; Pioglitazone; Rosiglitazone; Thiazolidinediones; Troglitazone | 2006 |
Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.
Topics: Albuminuria; Animals; Blood Pressure; Chromans; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelin-1; Humans; Hypoglycemic Agents; Kidney; Kidney Failure, Chronic; Pioglitazone; PPAR gamma; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors; Troglitazone | 2006 |
Beta-cell preservation with thiazolidinediones.
Topics: Chromans; Diabetes Mellitus; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Pioglitazone; Rosiglitazone; Thiazolidinediones; Troglitazone | 2007 |
New oral agents for type 2 diabetes.
Topics: Acarbose; Carbamates; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Piperidines; Pyrazoles; Rimonabant; Thiazolidinediones; Troglitazone | 2007 |
Use of insulin sensitizers in NASH.
Topics: Alanine Transaminase; Chromans; Fatty Liver; Humans; Insulin Resistance; Metabolic Syndrome; Metformin; Pioglitazone; Prognosis; Rosiglitazone; Thiazolidinediones; Troglitazone | 2007 |
[Adverse effects of insulin sensitisers and biguanides].
Topics: Acidosis, Lactic; Animals; Biguanides; Capillary Permeability; Chemical and Drug Induced Liver Injury; Chromans; Edema; Gastrointestinal Diseases; Humans; Hypoglycemic Agents; Pioglitazone; PPAR gamma; Sodium; Thiazolidinediones; Troglitazone; Weight Gain | 2007 |
Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus; Humans; Pharmacogenetics; Pioglitazone; Precision Medicine; Risk Factors; Rosiglitazone; Thiazolidinediones; Troglitazone | 2014 |
5 trial(s) available for troglitazone and pioglitazone
| Article | Year |
|---|---|
A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones.
Topics: Body Weight; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2000 |
Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects.
Topics: Administration, Oral; Adult; Analysis of Variance; Area Under Curve; Chromans; Confidence Intervals; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Female; Headache; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Simvastatin; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Male; Metformin; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2002 |
Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes.
Topics: Adult; Carotid Artery Diseases; Chromans; Diabetes Mellitus, Type 2; Diabetes, Gestational; Disease Progression; Female; Follow-Up Studies; Hispanic or Latino; Humans; Hypoglycemic Agents; Middle Aged; Pioglitazone; Placebos; Pregnancy; Premenopause; Risk Factors; Severity of Illness Index; Thiazolidinediones; Troglitazone | 2008 |
Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide-Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes.
Topics: Adipocytes; Diabetes Mellitus, Type 2; Double-Blind Method; Gastric Inhibitory Polypeptide; Gene Expression Regulation; Glucose; Humans; Hypoglycemic Agents; Insulin Secretion; Pioglitazone; PPAR gamma; Receptors, Cell Surface; Troglitazone | 2020 |
151 other study(ies) available for troglitazone and pioglitazone
| Article | Year |
|---|---|
[[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Hemoglobins; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Structure-Activity Relationship; Thiazoles | 1994 |
Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma.
Topics: 3T3 Cells; Adipocytes; Animals; Benzoxazoles; Female; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Phenylpropionates; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Transcription Factors | 1998 |
Isoxazolidine-3,5-dione and noncyclic 1,3-dicarbonyl compounds as hypoglycemic agents.
Topics: 3T3 Cells; Animals; Blood Glucose; Cell Differentiation; Drug Evaluation, Preclinical; Hypoglycemic Agents; Insulin; Isoxazoles; L Cells; Male; Malonates; Mice; Oxazoles; Triglycerides | 1998 |
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
Topics: Administration, Oral; Aminopyridines; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; DNA-Binding Proteins; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Ligands; Lipids; Male; Mice; Oxazoles; Propionates; Radioligand Assay; Rats; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Stereoisomerism; Structure-Activity Relationship; Transcription Factors; Transfection; Tyrosine | 1998 |
(3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents.
Topics: Animals; Blood Glucose; Hypoglycemic Agents; Insulin; Mice; Mice, Obese; Pioglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Thiazolidines; Triglycerides | 1999 |
Synthesis and biological activity of a novel series of indole-derived PPARgamma agonists.
Topics: Animals; Biological Availability; Humans; Indoles; Rats; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship; Transcription Factors | 1999 |
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
Topics: Animals; Blood Glucose; Carbazoles; Cholesterol; Cholesterol, Dietary; Crystallography, X-Ray; Drug Evaluation, Preclinical; Glucose Tolerance Test; Hypoglycemic Agents; Hypolipidemic Agents; Male; Mice; Models, Molecular; Nuclear Proteins; Phenylpropionates; Pioglitazone; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2002 |
Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity.
Topics: Biological Transport, Active; Chemical and Drug Induced Liver Injury; Chromans; Cloning, Molecular; DNA, Complementary; Estrone; Hepatocytes; Humans; Hypoglycemic Agents; Molecular Sequence Data; Oocytes; Organic Anion Transporters; Pioglitazone; Protein Binding; Quinones; Reverse Transcriptase Polymerase Chain Reaction; Thiazolidinediones; Troglitazone | 2004 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Thiazolidinedione derivatives as PTP1B inhibitors with antihyperglycemic and antiobesity effects.
Topics: Animals; Anti-Obesity Agents; Binding Sites; Blood Glucose; Catalytic Domain; Computer Simulation; Enzyme Inhibitors; Hypoglycemic Agents; Mice; Phenyl Ethers; PPAR gamma; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Thiazolidinediones | 2009 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening.
Topics: Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs.
Topics: | 2011 |
Sesquiterpene lactones from Tithonia diversifolia act as peroxisome proliferator-activated receptor agonists.
Topics: Diabetes Mellitus; Drugs, Chinese Herbal; Hep G2 Cells; Humans; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Lactones; Molecular Structure; Plants; PPAR alpha; Sesquiterpenes; Signal Transduction | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Structural insight of glitazone for hepato-toxicity: Resolving mystery by PASS.
Topics: Apoptosis; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Liver; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Thiazolidinediones | 2015 |
Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists.
Topics: Animals; Autoimmune Diseases; Cell Line; Cells, Cultured; Drug Discovery; HEK293 Cells; Humans; Imidazoles; Interleukin-17; Liver; Nuclear Receptor Subfamily 1, Group F, Member 3; Pyridines; Pyrimidines; Rats; Structure-Activity Relationship | 2015 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
PPARγ-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical development.
Topics: Dose-Response Relationship, Drug; Drug Design; Humans; Insulin Resistance; Molecular Structure; PPAR gamma; Structure-Activity Relationship; Thiazolidinediones | 2018 |
Selenium bioisosteric replacement of adenosine derivatives promoting adiponectin secretion increases the binding affinity to peroxisome proliferator-activated receptor δ.
Topics: Adenosine; Adiponectin; Cells, Cultured; Dose-Response Relationship, Drug; Humans; Mesenchymal Stem Cells; Molecular Docking Simulation; Molecular Structure; PPAR delta; Selenium; Structure-Activity Relationship | 2020 |
Design, synthesis, in-vitro, in-vivo and ex-vivo pharmacology of thiazolidine-2,4-dione derivatives as selective and reversible monoamine oxidase-B inhibitors.
Topics: Hydrazones; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship; Thiazolidines | 2022 |
Thiazolidinediones and fatty acids convert myogenic cells into adipose-like cells.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Actins; Adipose Tissue; Animals; Biomarkers; Carrier Proteins; Cell Differentiation; Cell Division; Chromans; Clone Cells; Creatine Kinase; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids, Nonesterified; Gene Expression; Glycerolphosphate Dehydrogenase; Hypoglycemic Agents; Linoleic Acid; Linoleic Acids; Mice; Muscles; Myelin P2 Protein; Myogenin; Neoplasm Proteins; Nerve Tissue Proteins; Palmitic Acid; Palmitic Acids; Phenotype; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 1995 |
Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats.
Topics: Animals; Chromans; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Glucose; Glucose Clamp Technique; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Pioglitazone; Rats; Rats, Wistar; Streptozocin; Thiazoles; Thiazolidinediones; Troglitazone | 1993 |
A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs.
Topics: Adipose Tissue; Amino Acid Sequence; Animals; Base Sequence; Benzopyrans; Chromans; DNA, Complementary; Fatty Acids; Humans; Mice; Molecular Sequence Data; Pioglitazone; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Troglitazone | 1996 |
Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats.
Topics: Animals; Caprylates; Carnitine O-Palmitoyltransferase; Cells, Cultured; Chromans; Coenzyme A Ligases; Fasting; Gluconeogenesis; Hypoglycemic Agents; Ketone Bodies; Kinetics; Liver; Male; Microsomes, Liver; Oleic Acid; Oxidation-Reduction; Phospholipids; Pioglitazone; Rats; Rats, Wistar; Repressor Proteins; Saccharomyces cerevisiae Proteins; Starvation; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 1996 |
"Glitazones", a prospect for non-insulin-dependent diabetes.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Troglitazone has a scavenging effect on reactive oxygen species.
Topics: Antioxidants; Chromans; Cytochrome c Group; Dimethyl Sulfoxide; Electron Spin Resonance Spectroscopy; Free Radical Scavengers; Humans; Hydrogen Peroxide; Iron; Molecular Structure; Neutrophils; Pioglitazone; Reactive Oxygen Species; Spin Labels; Tetradecanoylphorbol Acetate; Thiazoles; Thiazolidinediones; Troglitazone; Vitamin E; Xanthine; Xanthine Oxidase; Xanthines | 1997 |
Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling.
Topics: 3T3 Cells; Adipocytes; Animals; Chromans; Drug Interactions; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Ligands; Mice; NF-kappa B; Phosphoproteins; Phosphorylation; Pioglitazone; Receptor, Insulin; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Necrosis Factor-alpha | 1997 |
Thiazolidinediones downregulate stearoyl-CoA desaturase 1 gene expression in 3T3-L1 adipocytes.
Topics: 3T3 Cells; Adipocytes; Animals; Blotting, Northern; Chromans; DNA Probes; Fatty Acids; Gene Expression Regulation; Hypoglycemic Agents; Mice; Pioglitazone; RNA, Messenger; Stearoyl-CoA Desaturase; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Novel benzoxazole 2,4-thiazolidinediones as potent hypoglycemic agents. Synthesis and structure-activity relationships.
Topics: Animals; Benzopyrans; Benzoxazoles; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Male; Mice; Obesity; Pioglitazone; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Effects of troglitazone and pioglitazone on cytokine-mediated endothelial cell proliferation in vitro.
Topics: Animals; Cell Division; Chromans; Endothelium, Vascular; Fibroblast Growth Factor 2; Hypoglycemic Agents; Insulin; Mice; Mice, Inbred BALB C; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism.
Topics: Adenosine Diphosphate; Blood Platelets; Blood Proteins; Chromans; Collagen; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Hypoglycemic Agents; In Vitro Techniques; Isoenzymes; Kinetics; Phosphatidylinositol 3-Kinases; Phosphatidylinositols; Phosphorylation; Pioglitazone; Platelet Aggregation; Platelet Aggregation Inhibitors; Protein Kinase C; Protein Kinase C beta; Protein Kinase C-alpha; Thiazoles; Thiazolidinediones; Thrombin; Troglitazone; Vitamin E | 1998 |
Effects of troglitazone and pioglitazone on the action potentials and membrane currents of rabbit ventricular myocytes.
Topics: Action Potentials; Animals; Chromans; Heart Ventricles; In Vitro Techniques; Male; Membrane Potentials; Pioglitazone; Rabbits; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function.
Topics: Animals; Cattle; Cells, Cultured; Chromans; Endothelin-1; Endothelium, Vascular; Hypoglycemic Agents; Insulin; Pioglitazone; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 1999 |
Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative.
Topics: 3T3 Cells; Administration, Oral; Animals; Blood Glucose; Cell Differentiation; Chromans; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucose; Hyperinsulinism; Hypertriglyceridemia; Hypoglycemic Agents; Insulin; Isoxazoles; Male; Mice; Mice, Inbred Strains; Oxidation-Reduction; Pioglitazone; Rats; Rats, Sprague-Dawley; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Troglitazone | 1999 |
Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.
Topics: Base Sequence; Cells, Cultured; Chromans; DNA Primers; Down-Regulation; Endothelium, Vascular; Humans; Pioglitazone; Plasminogen Activator Inhibitor 1; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Necrosis Factor-alpha | 1999 |
Troglitazone and pioglitazone attenuate agonist-dependent Ca2+ mobilization and cell proliferation in vascular smooth muscle cells.
Topics: Animals; Calcium; Calcium Channels, L-Type; Cell Division; Cell Line; Chromans; Hypoglycemic Agents; Membrane Potentials; Muscle, Smooth, Vascular; Pioglitazone; Platelet-Derived Growth Factor; Prostaglandin D2; Rats; Thiazoles; Thiazolidinediones; Troglitazone; Vasopressins | 1999 |
Troglitazone but not pioglitazone affects ATP-sensitive K(+) channel activity.
Topics: Adenosine Triphosphate; Animals; ATP-Binding Cassette Transporters; Chromans; COS Cells; Diazoxide; Electrophysiology; Glyburide; Membrane Potentials; Pinacidil; Pioglitazone; Potassium Channels; Potassium Channels, Inwardly Rectifying; Receptors, Drug; Recombinant Fusion Proteins; Rubidium Radioisotopes; Sulfonylurea Receptors; Thiazoles; Thiazolidinediones; Transfection; Troglitazone | 1999 |
Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro.
Topics: Acid Phosphatase; Adipocytes; Animals; Bone Marrow Cells; Bone Resorption; Calcitriol; Cell Differentiation; Cells, Cultured; Chromans; Hypoglycemic Agents; Interleukin-11; Isoenzymes; Mice; Mice, Inbred ICR; Osteoclasts; Parathyroid Hormone; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Tartrate-Resistant Acid Phosphatase; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 1999 |
In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone.
Topics: Chromans; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Hypoglycemic Agents; In Vitro Techniques; Isoenzymes; Kinetics; Microsomes, Liver; Oxidation-Reduction; Pioglitazone; Recombinant Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Xenobiotics | 2000 |
The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice.
Topics: 3T3 Cells; Adipose Tissue; Animals; Blood Glucose; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; Hyperglycemia; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Mice, Transgenic; Oxadiazoles; Pioglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone; Weight Gain | 2000 |
Thiazolidinediones exert different effects on insulin resistance between dexamethasone-treated rats and wistar fatty rats.
Topics: Animals; Chromans; Dexamethasone; Drug Combinations; Glucocorticoids; Glucose; Glucose Clamp Technique; Homeostasis; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Obesity; Pioglitazone; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells.
Topics: Acetophenones; Cells, Cultured; Chromans; Endothelial Growth Factors; Gene Expression Regulation; Humans; Lymphokines; Muscle, Smooth, Vascular; Peroxisome Proliferators; Pioglitazone; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Tetrazoles; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Troglitazone; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vasodilator Agents | 2000 |
How should patients taking the discontinued diabetes drug troglitazone be managed?
Topics: Alanine Transaminase; Chromans; Diabetes Mellitus; Humans; Hypoglycemic Agents; Liver; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats.
Topics: Albuminuria; Animals; Chromans; Diabetes Mellitus, Experimental; Diglycerides; Extracellular Matrix Proteins; Hemodynamics; Insulin; Kidney Glomerulus; Male; Mitogen-Activated Protein Kinases; Pioglitazone; Protein Kinase C; Rats; Rats, Sprague-Dawley; Renal Circulation; RNA, Messenger; Thiazoles; Thiazolidinediones; Transforming Growth Factor beta; Troglitazone | 2000 |
Acute hemodynamic effects of insulin-sensitizing agents in isolated perfused rat hearts.
Topics: Animals; Chromans; Dose-Response Relationship, Drug; Hemodynamics; Hypoglycemic Agents; Indomethacin; Isoxazoles; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Perfusion; Pioglitazone; Prostaglandins; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Vitamin E | 2000 |
Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Contraindications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
The effect of activation of peroxisome proliferator-activated receptor gamma (PPARgamma) on human monocyte function: PPARgamma ligands do not inhibit tumor necrosis factor-alpha release in human monocytic cell line THP-1.
Topics: Antineoplastic Agents; Carcinogens; Cell Survival; Cells, Cultured; Chromans; Humans; Hypoglycemic Agents; Ligands; Monocytes; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Tetradecanoylphorbol Acetate; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Necrosis Factor-alpha | 2000 |
Information on thiazolidinediones.
Topics: Chromans; Drug Industry; Humans; Hypoglycemic Agents; Internet; Ligands; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States; United States Food and Drug Administration | 2000 |
[New development in diabetes therapy. 35th Annual Meeting of the German Diabetes Society, Munich, May 5-June 3, 2000].
Topics: Chromans; Diabetes Mellitus, Type 2; Germany; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Insulin sensitizer. A new therapy option for type 2 diabetic patients].
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells.
Topics: Animals; Apoptosis; Cell Survival; Cells, Cultured; Chromans; GADD45 Proteins; Gene Expression; Hypoglycemic Agents; Intracellular Signaling Peptides and Proteins; Male; Muscle, Smooth, Vascular; Pioglitazone; Platelet Aggregation Inhibitors; Proteins; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Suppressor Protein p53 | 2000 |
15-Deoxy-Delta(12,14)-prostaglandin J(2) facilitates thyroglobulin production by cultured human thyrocytes.
Topics: Anticholesteremic Agents; Arsenites; Bucladesine; Cells, Cultured; Chromans; Cyclic AMP; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fetal Proteins; Gene Expression Regulation, Enzymologic; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Humans; Hypoglycemic Agents; Ligands; Membrane Proteins; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Pioglitazone; Prostaglandin D2; Pyrimidines; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Sodium Compounds; Thiazoles; Thiazolidinediones; Thyroglobulin; Thyroid Gland; Thyrotropin; Transcription Factors; Troglitazone | 2000 |
Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone.
Topics: Animals; Apolipoprotein A-I; Bezafibrate; Chlorocebus aethiops; Chromans; COS Cells; Fenofibrate; Gene Expression Regulation; Humans; Hypoglycemic Agents; Kinetics; Pioglitazone; Protein Isoforms; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Transfection; Troglitazone; Tumor Cells, Cultured | 2000 |
Unraveling the mechanism of action of thiazolidinediones.
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Alteration in expression profiles of a series of diabetes-related genes in db/db mice following treatment with thiazolidinediones.
Topics: Adipocytes; Animals; Blood Glucose; Body Weight; Chromans; Diabetes Mellitus, Experimental; Female; Gene Expression; Gene Expression Profiling; Hypoglycemic Agents; Liver; Mice; Muscles; Pioglitazone; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2000 |
The transcription factor Fos-related antigen 1 is induced by thiazolidinediones during differentiation of 3T3-L1 cells.
Topics: 3T3 Cells; Animals; Cell Differentiation; Cell Nucleus; Chromans; Dimerization; Dose-Response Relationship, Drug; Gene Expression Regulation; Hypoglycemic Agents; Mice; Pioglitazone; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Receptors, Cytoplasmic and Nuclear; RNA Stability; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Troglitazone; Up-Regulation | 2001 |
Survival activity of troglitazone in rat motoneurones.
Topics: Animals; Antioxidants; Brain-Derived Neurotrophic Factor; Cell Survival; Cells, Cultured; Chromans; Drug Evaluation, Preclinical; Enzyme Activation; Enzyme Inhibitors; Hippocampus; Insulin-Like Growth Factor I; Motor Neurons; Neurons, Afferent; Phosphoinositide-3 Kinase Inhibitors; Pioglitazone; Rats; Receptors, Cytoplasmic and Nuclear; Septum of Brain; Spinal Cord; Sympathetic Nervous System; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
Does pioglitazone, like troglitazone, increase serum levels of lipoprotein(a) in diabetic patients?
Topics: Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipoprotein(a); Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta -hydroxysteroid dehydrogenase.
Topics: 3-Hydroxysteroid Dehydrogenases; Biguanides; Chromans; Cloning, Molecular; Humans; Kinetics; Metformin; Pioglitazone; Recombinant Proteins; Saccharomyces cerevisiae; Steroid 17-alpha-Hydroxylase; Steroid Hydroxylases; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Administration of troglitazone, but not pioglitazone, reduces insulin resistance caused by short-term dexamethasone (DXM) treatment by accelerating the metabolism of DXM.
Topics: Administration, Oral; Blood Glucose; Chromans; Dexamethasone; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metabolic Clearance Rate; Pioglitazone; Reference Values; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes.
Topics: alpha-Tocopherol; Animals; Cells, Cultured; Chromans; Gene Expression; Hypoglycemic Agents; Muscle, Smooth, Vascular; Pioglitazone; Promoter Regions, Genetic; Rats; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Receptors, Cytoplasmic and Nuclear; Receptors, Thromboxane; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Troglitazone | 2001 |
Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle.
Topics: Analysis of Variance; Animals; Barium; Calcium; Chromans; Dose-Response Relationship, Drug; Electric Stimulation; Female; Guinea Pigs; Humans; Insulin Resistance; Ion Channels; Isoxazoles; Membrane Potentials; Muscle, Smooth, Vascular; Pioglitazone; Potassium Channels; Prostaglandin D2; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Actos (pioglitazone HCL) provides a safe, effective alternative for patients formerly taking Rezulin.
Topics: Chromans; Clinical Trials as Topic; Consumer Product Safety; Diabetes Mellitus, Type 2; Drug Industry; Humans; Hypoglycemic Agents; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States | 2000 |
Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells.
Topics: Aged; Blotting, Western; Cell Division; Cell Line; Chromans; Dose-Response Relationship, Drug; Humans; Immunologic Factors; Ligands; Male; Pioglitazone; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transfection; Troglitazone; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Urothelium | 2001 |
Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides.
Topics: Animals; Arteriosclerosis; Carotid Arteries; Cattle; Cell Division; Cells, Cultured; Chromans; Coronary Vessels; Dose-Response Relationship, Drug; Endothelins; Endothelium, Vascular; Gene Expression; Humans; Hypoglycemic Agents; Natriuretic Peptide, C-Type; Pioglitazone; Radioimmunoassay; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Vasodilator Agents; Vasomotor System | 2001 |
PPARgamma ligands inhibit TNF-alpha-induced LOX-1 expression in cultured endothelial cells.
Topics: Animals; Arteriosclerosis; Cattle; Cells, Cultured; Chromans; Drug Antagonism; Endothelium; Immunohistochemistry; Pioglitazone; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; Receptors, Oxidized LDL; RNA, Messenger; Tetradecanoylphorbol Acetate; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Troglitazone; Tumor Necrosis Factor-alpha | 2001 |
Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Renal Cell; Cell Division; Chromans; Coloring Agents; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Immunohistochemistry; Immunologic Factors; Kidney Neoplasms; Ligands; Pioglitazone; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazolium Salts; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Cells, Cultured; Up-Regulation | 2001 |
Cellular mechanisms in the development and progression of diabetic nephropathy: activation of the DAG-PKC-ERK pathway.
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diacylglycerol Kinase; Disease Progression; Enzyme Activation; Glomerular Mesangium; Isoenzymes; Mice; Mitogen-Activated Protein Kinases; Pioglitazone; Plant Proteins; Protein Kinase C; Protein Kinase C beta; Rats; Signal Transduction; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
15-Deoxy-delta 12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells.
Topics: Androstadienes; Animals; Cells, Cultured; Chromans; Enzyme Activation; Enzyme Inhibitors; Immunologic Factors; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Pioglitazone; Prostaglandin D2; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazoles; Thiazolidinediones; Thymidine; Transcription Factors; Troglitazone; Wortmannin | 2001 |
Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Survival; Chromans; DNA Fragmentation; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Tetrazolium Salts; Thiazoles; Thiazolidinediones; Troglitazone; Tumor Cells, Cultured | 2001 |
Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo.
Topics: Actins; Angiotensin II; Animals; Atrial Natriuretic Factor; Body Weight; Cardiomegaly; Cell Size; Cells, Cultured; Chromans; Disease Models, Animal; Gene Expression; Heart; Heterozygote; Hypoglycemic Agents; Ligands; Mice; Mice, Knockout; Myocardium; Organ Size; Pioglitazone; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2002 |
Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success.
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
PPAR gamma ligands, troglitazone and pioglitazone, up-regulate expression of HMG-CoA synthase and HMG-CoA reductase gene in THP-1 macrophages.
Topics: Cell Differentiation; Cell Line; Cholesterol; Chromans; Coenzyme A Ligases; DNA, Antisense; Dose-Response Relationship, Drug; Gene Expression Regulation; Gene Expression Regulation, Enzymologic; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Synthase; Macrophages; Oligonucleotides; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Response Elements; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Up-Regulation | 2002 |
Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats.
Topics: Analysis of Variance; Animals; Cardiomegaly; Chromans; Endothelin-1; Endothelins; Male; Natriuretic Peptide, Brain; Pioglitazone; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stimulation, Chemical; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2002 |
Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists.
Topics: Antineoplastic Agents; Apoptosis; Cell Division; Chromans; Dinoprostone; Gene Expression Regulation, Neoplastic; Growth Inhibitors; Humans; Immunohistochemistry; Ligands; Male; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; Testicular Neoplasms; Testis; Thiazoles; Thiazolidinediones; Thiazolidines; Transcription Factors; Troglitazone; Tumor Cells, Cultured | 2002 |
[Meta-analysis shows: insulin sensitizer is safe for the liver].
Topics: Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis.
Topics: Acute Disease; Animals; Antibody Formation; Antioxidants; Chromans; Colitis; Cytokines; Disease Models, Animal; Hypoglycemic Agents; Ligands; Mice; Mice, Inbred C57BL; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Th2 Cells; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2002 |
Did this drug cause my patient's hepatitis?
Topics: Chemical and Drug Induced Liver Injury; Chromans; Humans; Pioglitazone; Product Surveillance, Postmarketing; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice.
Topics: Animals; Antineoplastic Agents; Azoxymethane; Carcinogens; Chromans; Colon; Colonic Neoplasms; Female; Immunohistochemistry; Ligands; Mice; Mice, Inbred BALB C; Pioglitazone; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2003 |
Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats.
Topics: Acetylcholine; Animals; Aorta, Thoracic; Arteriosclerosis; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Endothelium, Vascular; Hypoglycemic Agents; Isometric Contraction; Lipid Peroxidation; Lipids; Male; Metformin; Muscle Contraction; Muscle Relaxation; Oxidation-Reduction; Pioglitazone; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilator Agents | 2003 |
Metformin, but not thiazolidinediones, inhibits plasminogen activator inhibitor-1 production in human adipose tissue in vitro.
Topics: Adipocytes; Adipose Tissue; Adult; Cells, Cultured; Chromans; Culture Techniques; Dose-Response Relationship, Drug; Female; Humans; Hypoglycemic Agents; Kinetics; Metformin; Pioglitazone; Plasminogen Activator Inhibitor 1; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Thiazolidinediones; Transcription Factors; Troglitazone | 2003 |
Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects.
Topics: Adult; CD36 Antigens; Cells, Cultured; Chromans; Diabetes Mellitus, Type 2; Fatty Acids; Fatty Acids, Nonesterified; Female; Gene Expression; Humans; Insulin Resistance; Male; Membrane Glycoproteins; Middle Aged; Muscle, Skeletal; Organic Anion Transporters; Oxidation-Reduction; Palmitic Acid; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation.
Topics: Becaplermin; Cell Count; Cell Cycle; Cell Division; Cells, Cultured; Chromans; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Insulin; Ligands; Mammary Arteries; Mitogens; Muscle, Smooth, Vascular; Phosphorylation; Pioglitazone; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Radial Artery; Receptors, Cytoplasmic and Nuclear; Retinoblastoma Protein; Rosiglitazone; Saphenous Vein; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2003 |
Regulation of MMP-1 expression in vascular endothelial cells by insulin sensitizing thiazolidinediones.
Topics: Cells, Cultured; Chromans; Cysteine; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Eukaryotic Initiation Factors; Humans; Hypoglycemic Agents; Immunoblotting; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Methionine; Pioglitazone; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Troglitazone; Umbilical Veins | 2003 |
Thiazolidinediones inhibit cell growth of human oral squamous cell carcinoma in vitro independent of peroxisome proliferator-activated receptor gamma.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Chromans; DNA Mutational Analysis; Humans; Mouth Neoplasms; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazolidinediones; Transcription Factors; Transfection; Troglitazone | 2003 |
Suppression of experimental crescentic glomerulonephritis by peroxisome proliferator-activated receptor (PPAR)gamma activators.
Topics: Animals; Anti-Glomerular Basement Membrane Disease; Antibodies; Autoantibodies; CD8-Positive T-Lymphocytes; Chromans; Kidney Glomerulus; Kinetics; Macrophages; Male; Monocytes; Pioglitazone; Proteinuria; Rabbits; Rats; Rats, Inbred WKY; Receptors, Cytoplasmic and Nuclear; Thiazolidinediones; Transcription Factors; Troglitazone | 2003 |
Novel PPARgamma-dependent and independent effects for thiazolidinediones.
Topics: Animals; Bezafibrate; Body Weight; Chromans; Diabetes Mellitus, Type 2; Gene Expression; Humans; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Proteins; Mice; Monocytes; Pancreas; Pioglitazone; PPAR alpha; PPAR gamma; Pregnancy Proteins; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Troglitazone; Tumor Necrosis Factor-alpha | 2003 |
Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones.
Topics: Adipocytes; Adipose Tissue; Cells, Cultured; Chromans; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Plasminogen Activator Inhibitor 1; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transcription, Genetic; Troglitazone | 2004 |
Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2.
Topics: Angiotensin II; Animals; Blood Pressure; Cell Cycle Proteins; Cells, Cultured; Chromans; Hypertension; Intracellular Signaling Peptides and Proteins; Ligands; Male; Muscle, Smooth, Vascular; Pioglitazone; Platelet-Derived Growth Factor; PPAR gamma; Protein Phosphatase 2; Protein Serine-Threonine Kinases; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-vav; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Sprague-Dawley; rho GTP-Binding Proteins; rho-Associated Kinases; Signal Transduction; Thiazolidinediones; Troglitazone | 2004 |
Effects of PPARgamma ligands and C/EBPbeta enhancer on expression of extracellular-superoxide dismutase.
Topics: CCAAT-Enhancer-Binding Protein-beta; Cell Line; Chromans; Diabetes Mellitus, Type 2; DNA Primers; Extracellular Fluid; Fibroblasts; Humans; Hypoglycemic Agents; Ligands; Pioglitazone; Plasmids; PPAR gamma; Promoter Regions, Genetic; RNA, Messenger; Superoxide Dismutase; Thiazolidinediones; Troglitazone | 2004 |
Peroxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats.
Topics: Alkylating Agents; Animals; Anticarcinogenic Agents; Chromans; Diethylnitrosamine; Gene Expression; Glutathione Transferase; Hypoglycemic Agents; Immunohistochemistry; Ligands; Liver Neoplasms; Male; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Troglitazone | 2004 |
A yeast two-hybrid technology-based system for the discovery of PPARgamma agonist and antagonist.
Topics: alpha-Galactosidase; Anilides; Cells, Cultured; Chromans; CREB-Binding Protein; Drug Evaluation, Preclinical; Genes, Reporter; Indomethacin; Ligands; Nuclear Proteins; Oxazoles; Pioglitazone; PPAR gamma; Prostaglandin D2; Protein Binding; Rosiglitazone; Thiazolidinediones; Trans-Activators; Troglitazone; Two-Hybrid System Techniques; Tyrosine; Yeasts | 2004 |
Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide.
Topics: Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Anilides; Animals; Aspartic Acid Endopeptidases; Cell Line; Cell Line, Tumor; Cells, Cultured; Cerebral Cortex; Chromans; Culture Media, Conditioned; Endopeptidases; Humans; Kidney; Mice; Neuroblastoma; Neuroglia; Neurons; Peptide Fragments; Pioglitazone; PPAR gamma; Protein Processing, Post-Translational; Receptor, Notch1; Receptors, Cell Surface; Recombinant Fusion Proteins; Retinoid X Receptors; Rosiglitazone; Thiazolidinediones; Transcription Factors; Tretinoin; Troglitazone | 2004 |
Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia.
Topics: Animals; Blood Glucose; Brain Chemistry; Cell Count; Cerebrovascular Circulation; Chromans; Dose-Response Relationship, Drug; Encephalitis; Immunohistochemistry; Infarction, Middle Cerebral Artery; Ischemic Attack, Transient; Ligands; Macrophages; Male; Microglia; Middle Cerebral Artery; Nerve Tissue Proteins; Pioglitazone; PPAR gamma; Psychomotor Performance; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazolidinediones; Troglitazone | 2005 |
Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor gamma for monocyte recruitment and endothelial regeneration.
Topics: Alitretinoin; Angioplasty, Balloon; Animals; Aorta; Arteriosclerosis; Binding, Competitive; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CCL2; Chromans; Dose-Response Relationship, Drug; Endothelium, Vascular; Gene Expression Regulation; Humans; Macrophages; Male; Monocytes; Pioglitazone; PPAR gamma; Prostaglandin D2; Rabbits; Receptors, CCR2; Receptors, Chemokine; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazolidinediones; Time Factors; Tretinoin; Troglitazone; Vascular Endothelial Growth Factor A; Wound Healing | 2005 |
[Pexoxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats].
Topics: Animals; Antineoplastic Agents; Chromans; Diethylnitrosamine; Ligands; Liver Neoplasms, Experimental; Male; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
Improvement of liver function parameters in patients with type 2 diabetes treated with thiazolidinediones.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; gamma-Glutamyltransferase; Glycated Hemoglobin; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Pioglitazone; Thiazolidinediones; Troglitazone | 2005 |
PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer.
Topics: Amino Acid Motifs; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Chemokine CXCL1; Chemokine CXCL11; Chemokine CXCL5; Chemokines, CXC; Chemotaxis; Chromans; Culture Media, Conditioned; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Factor VIII; Humans; Immunohistochemistry; Intercellular Signaling Peptides and Proteins; Interleukin-8; Ligands; Lung Neoplasms; Mice; Mice, SCID; Microcirculation; Neoplasm Transplantation; Neovascularization, Pathologic; NF-kappa B; Pioglitazone; PPAR gamma; Proline; Thiazolidinediones; Thiocarbamates; Transfection; Troglitazone | 2005 |
Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
Topics: Aryl Hydrocarbon Hydroxylases; Automation; Chromans; Chromatography, Liquid; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Evaluation, Preclinical; Enzyme Inhibitors; Enzyme Reactivators; Humans; In Vitro Techniques; Kinetics; Mass Spectrometry; Microsomes, Liver; Mixed Function Oxygenases; Pharmaceutical Preparations; Pioglitazone; Reproducibility of Results; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
Thiazolidinediones inhibit apoptosis and heat shock protein 60 expression in human vascular endothelial cells.
Topics: Aorta; Apoptosis; Blotting, Western; Caspases; Cell Cycle Proteins; Cell Proliferation; Cells, Cultured; Chaperonin 60; Chromans; DNA-Binding Proteins; Dose-Response Relationship, Drug; E2F Transcription Factors; E2F1 Transcription Factor; Endothelium, Vascular; Enzyme Activation; Humans; Hypoglycemic Agents; Ligands; Microscopy, Phase-Contrast; Mitochondria; Pioglitazone; PPAR gamma; Prostaglandin D2; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Rosiglitazone; Thiazolidinediones; Time Factors; Transcription Factors; Troglitazone; Tumor Necrosis Factor-alpha; von Willebrand Factor | 2005 |
Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Chromans; Humans; Kidney Neoplasms; Ligands; Pioglitazone; PPAR gamma; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Thiazolidinediones; Troglitazone | 2005 |
Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture.
Topics: Adenocarcinoma, Follicular; Animals; Annexin A5; Apoptosis; Cell Differentiation; Cell Line, Transformed; Cell Proliferation; Chromans; Pioglitazone; PPAR gamma; Radiation-Sensitizing Agents; Retinoid X Receptor alpha; RNA, Messenger; Rosiglitazone; Swine; Symporters; Thiazolidinediones; Thyroglobulin; Thyroid Gland; Thyroid Neoplasms; Troglitazone | 2005 |
Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Anilides; Animals; Arachidonic Acids; Binding Sites; Binding, Competitive; Blotting, Western; Cannabinoid Receptor Modulators; Carrier Proteins; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Cell Line; Chlorocebus aethiops; Chromans; COS Cells; Dose-Response Relationship, Drug; Endocannabinoids; Fibroblasts; Gene Expression; HeLa Cells; Humans; Intercellular Signaling Peptides and Proteins; Luciferases; Mice; Perilipin-1; Phosphoproteins; Pioglitazone; Plasmids; Polyunsaturated Alkamides; PPAR gamma; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Thiazolidinediones; Transcriptional Activation; Transfection; Troglitazone | 2005 |
Regulation of adiponectin receptor 1 in human hepatocytes by agonists of nuclear receptors.
Topics: Adiponectin; Alitretinoin; Animals; Caco-2 Cells; Cell Line; CHO Cells; Chromans; Cricetinae; DNA-Binding Proteins; Fenofibrate; HeLa Cells; Hepatocytes; Humans; Hydroxycholesterols; Liver X Receptors; Orphan Nuclear Receptors; Peroxisome Proliferator-Activated Receptors; Pioglitazone; PPAR alpha; Receptors, Adiponectin; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Retinoid X Receptors; Thiazolidinediones; Tretinoin; Troglitazone; Up-Regulation | 2005 |
Rating the severity of the medical consequences of drug-induced liver injury.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Data Collection; Humans; Hypoglycemic Agents; Liver; Liver Function Tests; Pioglitazone; Risk Assessment; Rosiglitazone; Surveys and Questionnaires; Thiazolidinediones; Troglitazone | 2005 |
Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.
Topics: Adult; Aged; Case-Control Studies; Chromans; Diabetes Mellitus, Type 2; Female; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Male; Medicaid; Middle Aged; Pioglitazone; Retrospective Studies; Risk; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
Insulin-lowering agents inhibit synthesis of testosterone in ovaries of DHEA-induced PCOS rats.
Topics: 17-Hydroxysteroid Dehydrogenases; Adjuvants, Immunologic; Animals; Chromans; Dehydroepiandrosterone; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Hypoglycemic Agents; Immunohistochemistry; Insulin; Metformin; Ovary; Pioglitazone; Polycystic Ovary Syndrome; Rats; Rats, Wistar; Testosterone; Thiazolidinediones; Troglitazone | 2006 |
Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry.
Topics: Animals; Chromans; Chromatography, Liquid; Glutathione; Humans; Hypoglycemic Agents; In Vitro Techniques; Isotope Labeling; Mass Spectrometry; Microsomes, Liver; Pioglitazone; Rats; Rosiglitazone; Thiazolidinediones; Troglitazone | 2006 |
A Ligand for peroxisome proliferator-activated receptor gamma inhibits human cholangiocarcinoma cell growth: potential molecular targeting strategy for cholangioma.
Topics: Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Caspase 3; Caspase 9; Caspases; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Chromans; Humans; Ligands; Molecular Biology; Pioglitazone; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Thiazolidinediones; Troglitazone | 2006 |
Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells.
Topics: Animals; Carcinoma, Hepatocellular; Cells, Cultured; Chromans; Cluster Analysis; Gene Expression Profiling; Gene Expression Regulation; Hepatocytes; Humans; Hypoglycemic Agents; Liver Neoplasms; Pioglitazone; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Transcription, Genetic; Troglitazone | 2006 |
Troglitazone and pioglitazone interactions via PPAR-gamma-independent and -dependent pathways in regulating physiological responses in renal tubule-derived cell lines.
Topics: Animals; Cell Line; Chromans; Drug Combinations; Hydrogen-Ion Concentration; Kidney Tubules; Pioglitazone; PPAR gamma; Signal Transduction; Swine; Thiazolidinediones; Troglitazone | 2007 |
Rosiglitazone inhibits mouse liver regeneration.
Topics: Animals; Chromans; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Gene Expression Regulation; Interleukin-6; Liver Regeneration; Male; Mice; Mice, Inbred C57BL; p38 Mitogen-Activated Protein Kinases; Pioglitazone; PPAR gamma; RNA, Messenger; Rosiglitazone; S-Phase Kinase-Associated Proteins; Signal Transduction; STAT3 Transcription Factor; Thiazolidinediones; Troglitazone; Tumor Necrosis Factor-alpha; Vasodilator Agents | 2006 |
Genetic analysis of peroxisome proliferator-activated receptor gamma1 splice variants in human colorectal cell lines.
Topics: Base Sequence; Caco-2 Cells; Chromans; Chromosome Mapping; Colonic Neoplasms; Cycloheximide; Dactinomycin; Exons; HCT116 Cells; HT29 Cells; Humans; Pioglitazone; PPAR gamma; Protein Isoforms; RNA, Messenger; Thiazolidinediones; Troglitazone; Untranslated Regions | 2006 |
Diabetes drugs tied to fractures in women.
Topics: Chromans; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones; Troglitazone | 2007 |
Comparison of vascular relaxation, lipolysis and glucose uptake by peroxisome proliferator-activated receptor-gamma activation in +db/+m and +db/+db mice.
Topics: Abdominal Fat; Adipocytes; Animals; Aorta, Thoracic; Carbohydrate Metabolism; Chromans; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Glucose; Hypoglycemic Agents; In Vitro Techniques; Insulin; Lipid Metabolism; Lipolysis; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Obesity; Pioglitazone; PPAR gamma; RNA, Messenger; Thiazolidinediones; Troglitazone; Vasodilation | 2007 |
Investigation of the lipophilic behaviour of some thiazolidinediones. Relationships with PPAR-gamma activity.
Topics: Chromans; Chromatography, High Pressure Liquid; Hydrogen-Ion Concentration; Lipids; Membranes, Artificial; Octanols; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transcriptional Activation; Troglitazone; Water | 2007 |
Chemotherapeutic drugs induce PPAR-gamma expression and show sequence-specific synergy with PPAR-gamma ligands in inhibition of non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromans; Gene Expression Regulation, Neoplastic; Humans; Ligands; Lung Neoplasms; Mice; Mice, SCID; Neoplasm Transplantation; Pioglitazone; PPAR gamma; Thiazolidinediones; Troglitazone | 2008 |
Electrochemical oxidation of troglitazone: identification and characterization of the major reactive metabolite in liver microsomes.
Topics: Acetylcysteine; Animals; Chromans; Electrochemistry; Humans; Magnetic Resonance Spectroscopy; Microsomes, Liver; Molecular Structure; Oxidation-Reduction; Pioglitazone; Rats; Rosiglitazone; Thiazolidinediones; Troglitazone | 2008 |
Type 2 deiodinase expression is induced by peroxisomal proliferator-activated receptor-gamma agonists in skeletal myocytes.
Topics: Animals; Cells, Cultured; Chromans; Enzyme Activation; Immunohistochemistry; Insulin; Iodide Peroxidase; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle Fibers, Skeletal; Myoblasts; Pioglitazone; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazolidinediones; Troglitazone | 2009 |
Differential modulation of farnesoid X receptor signaling pathway by the thiazolidinediones.
Topics: Animals; Cell Line, Tumor; Chromans; Humans; Luciferases, Renilla; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Signal Transduction; Thiazolidinediones; Troglitazone | 2009 |
Peroxisome proliferator-activated receptor gamma antagonists decrease Na+ transport via the epithelial Na+ channel.
Topics: Anilides; Animals; Benzamides; Biological Transport; Cell Survival; CHO Cells; Chromans; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Epithelial Sodium Channels; Hypoglycemic Agents; Insulin; Membrane Potentials; Pioglitazone; PPAR gamma; Pyridines; Rosiglitazone; Sodium; Tetrazolium Salts; Thiazoles; Thiazolidinediones; Troglitazone | 2009 |
3T3-L1 adipocyte apoptosis induced by thiazolidinediones is peroxisome proliferator-activated receptor-gamma-dependent and mediated by the caspase-3-dependent apoptotic pathway.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Apoptosis; bcl-Associated Death Protein; Caspase 3; Chromans; Male; Mice; Pioglitazone; PPAR gamma; Prostaglandin D2; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Zucker; Thiazolidinediones; Troglitazone | 2010 |
Pioglitazone modulates tumor cell metabolism and proliferation in multicellular tumor spheroids.
Topics: Cell Line, Tumor; Cell Proliferation; Chromans; Deoxyglucose; Humans; Hydrogen-Ion Concentration; Hypoglycemic Agents; Lactic Acid; Male; Pioglitazone; PPAR gamma; Prostatic Neoplasms; Spheroids, Cellular; Thiazolidinediones; Troglitazone | 2011 |
Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor γ co-activator-1α protein.
Topics: Adenosine Triphosphate; Apoptosis; Carrier Proteins; Cell Survival; Chromans; Gene Expression Regulation; Heat-Shock Proteins; Hep G2 Cells; Humans; Hypoglycemic Agents; Mitochondria, Liver; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Pioglitazone; Reactive Oxygen Species; RNA-Binding Proteins; Rosiglitazone; Thiazolidinediones; Transcription Factors; Troglitazone | 2010 |
Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner.
Topics: Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromans; Female; Gene Expression; Humans; Ovarian Neoplasms; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Troglitazone | 2011 |
Evaluation of PPARγ agonists on rodent endothelial cell proliferation.
Topics: Adipose Tissue; Animals; Apoptosis; Body Weight; Cell Proliferation; Chromans; DNA; Endothelial Cells; Female; Hepatocytes; Mice; Organ Size; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; Thiazolidinediones; Troglitazone | 2011 |
Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery.
Topics: Animals; Cell Line; Cell Membrane; Chromans; Drug Discovery; Gramicidin; Insulin; Ion Channels; Lipid Bilayers; Membrane Potentials; Membrane Proteins; Pioglitazone; PPAR gamma; Rats; Rosiglitazone; Sodium Channels; Thiazolidinediones; Troglitazone | 2011 |
The development of subcutaneous sarcomas in rodents exposed to peroxisome proliferators agonists: hypothetical mechanisms of action and de-risking attitude.
Topics: Adipogenesis; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; DNA Damage; Glycine; Hypoglycemic Agents; Ion Channels; Mice; Mitochondria; Mitochondrial Proteins; Oxazoles; Oxidative Stress; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Pioglitazone; PPAR alpha; PPAR gamma; Rats; RNA-Binding Proteins; Rodentia; Rosiglitazone; Sarcoma; Thermogenesis; Thiazolidinediones; Transcription Factors; Troglitazone; Uncoupling Protein 1 | 2012 |
Glitazones exert multiple effects on β-cell stimulus-secretion coupling.
Topics: Animals; Calcium; Calcium Channels, L-Type; Cattle; Cells, Cultured; Chromans; Cytosol; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; KATP Channels; Membrane Potentials; Mice; Mice, Inbred C57BL; Patch-Clamp Techniques; Pioglitazone; Potassium Channels, Voltage-Gated; Radioimmunoassay; Serum Albumin, Bovine; Thiazolidinediones; Troglitazone | 2013 |
Pyrrolidinediones reduce the toxicity of thiazolidinediones and modify their anti-diabetic and anti-cancer properties.
Topics: 3T3-L1 Cells; Animals; Antineoplastic Agents; Biotransformation; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromans; Dose-Response Relationship, Drug; Drug Design; Fatty Acid-Binding Proteins; Gene Expression Regulation; Glutathione; Humans; Hypoglycemic Agents; Liver Neoplasms; Mice; Microsomes, Liver; Molecular Structure; Phosphorylation; Pioglitazone; PPAR gamma; Protein Carbonylation; Receptor Protein-Tyrosine Kinases; Receptors, Peptide; Rosiglitazone; Structure-Activity Relationship; Succinimides; Thiazolidinediones; Troglitazone | 2012 |
PPARγ regulates the mitochondrial dysfunction in human neural stem cells with tumor necrosis factor alpha.
Topics: Adenosine Triphosphate; Adenylate Kinase; Caspase 3; Cell Survival; Chromans; Humans; Mitochondria; Neural Stem Cells; Oxidative Stress; Pioglitazone; PPAR gamma; Reactive Oxygen Species; Rosiglitazone; Signal Transduction; Sirtuin 1; Thiazolidinediones; Troglitazone; Tumor Necrosis Factor-alpha; Up-Regulation | 2013 |
Reversible inhibition of vasoconstriction by thiazolidinediones related to PI3K/Akt inhibition in vascular smooth muscle cells.
Topics: Anilides; Animals; Chromans; Dose-Response Relationship, Drug; Enzyme Inhibitors; Femoral Artery; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nitroarginine; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pioglitazone; PPAR gamma; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Troglitazone; Vasoconstriction | 2013 |
Troglitazone, a thiazolidinedione, decreases tau phosphorylation through the inhibition of cyclin-dependent kinase 5 activity in SH-SY5Y neuroblastoma cells and primary neurons.
Topics: Animals; Blotting, Western; Cells, Cultured; Cerebral Cortex; Chromans; Cyclin-Dependent Kinase 5; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Immunoprecipitation; Neurons; Phosphorylation; Pioglitazone; PPAR gamma; Protein Phosphatase 2; Rats; Rats, Sprague-Dawley; Rosiglitazone; tau Proteins; Thiazolidinediones; Transfection; Troglitazone | 2013 |
Various peroxisome proliferator-activated receptor (PPAR)-γ agonists differently induce differentiation of cultured human keratinocytes.
Topics: Anti-Inflammatory Agents; Benzimidazoles; Benzoates; Cell Differentiation; Cells, Cultured; Chromans; Filaggrin Proteins; Gene Expression Regulation; Humans; Intermediate Filament Proteins; Keratinocytes; Membrane Proteins; Microscopy, Fluorescence; Pioglitazone; PPAR gamma; RNA, Messenger; Rosiglitazone; Skin; Telmisartan; Thiazolidinediones; Troglitazone | 2015 |
Characterizing the mechanism of thiazolidinedione-induced hepatotoxicity: An in vitro model in mitochondria.
Topics: Cell Line, Tumor; Chromans; DNA, Mitochondrial; Electron Transport; Humans; Hypoglycemic Agents; Liver; Membrane Potential, Mitochondrial; Mitochondria; Oxidative Stress; Pioglitazone; Reactive Oxygen Species; Rosiglitazone; Thiazolidinediones; Troglitazone | 2015 |
Thiazolidinediones attenuate lipolysis and ameliorate dexamethasone-induced insulin resistance.
Topics: Adipocytes; Adipose Tissue; Animals; Chromans; Cyclic AMP; Dexamethasone; Diabetes Mellitus; Fatty Acids, Nonesterified; Glucocorticoids; Hydrolysis; Hypoglycemic Agents; Insulin Resistance; Lipolysis; Phosphorylation; Pioglitazone; Proto-Oncogene Proteins c-akt; Rats; Rosiglitazone; Signal Transduction; Thiazolidinediones; Triglycerides; Troglitazone | 2015 |
In Vivo Detection of Mitochondrial Dysfunction Induced by Clinical Drugs and Disease-Associated Genes Using a Novel Dye ZMJ214 in Zebrafish.
Topics: Animals; Anti-Bacterial Agents; Anticonvulsants; Benzophenones; Carbocyanines; Chromans; Disease Models, Animal; Fluorescent Dyes; Hypoglycemic Agents; Membrane Potential, Mitochondrial; Mitochondria; Nitrophenols; Oligomycins; Optical Imaging; Pioglitazone; Thiazolidinediones; Tolcapone; Toxicity Tests; Troglitazone; Zebrafish; Zebrafish Proteins | 2016 |
Activation of PPARγ does not contribute to macrophage ABCA1 expression and ABCA1-mediated cholesterol efflux to apoAI.
Topics: Animals; Apolipoprotein A-I; ATP Binding Cassette Transporter 1; CD36 Antigens; Cells, Cultured; Cholesterol; Chromans; Gene Deletion; Hypoglycemic Agents; Macrophages, Peritoneal; Mice, Inbred C57BL; Pioglitazone; PPAR gamma; RNA, Messenger; Thiazolidinediones; Transcriptional Activation; Troglitazone | 2017 |
The effects of troglitazone on AMPK in HepG2 cells.
Topics: AMP-Activated Protein Kinases; Chromans; Diabetes Mellitus, Type 2; Enzyme Activation; Hep G2 Cells; Humans; Hypoglycemic Agents; Insulin; Phosphorylation; Pioglitazone; Rosiglitazone; Thiazolidinediones; Troglitazone | 2017 |
Editor's Highlight: An Impaired Immune Tolerance Animal Model Distinguishes the Potential of Troglitazone/Pioglitazone and Tolcapone/Entacapone to Cause IDILI.
Topics: Animals; Antibodies, Monoclonal; Catechols; Cell Line; Chemical and Drug Induced Liver Injury; CTLA-4 Antigen; Disease Models, Animal; Female; Hepatocytes; Humans; Immune Tolerance; Inflammasomes; Macrophages; Mice, Inbred C57BL; Mice, Knockout; Nitriles; Pioglitazone; Programmed Cell Death 1 Receptor; Severity of Illness Index; Tolcapone; Troglitazone | 2018 |
Comprehensive Evaluation of Bile Acid Homeostasis in Human Hepatocyte Co-Culture in the Presence of Troglitazone, Pioglitazone, and Acetylsalicylic Acid.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bile Acids and Salts; Cells, Cultured; Chemical and Drug Induced Liver Injury; Coculture Techniques; Hepatocytes; Homeostasis; Humans; Hypoglycemic Agents; Pioglitazone; Troglitazone | 2019 |
3'Pool-seq: an optimized cost-efficient and scalable method of whole-transcriptome gene expression profiling.
Topics: Animals; Cost-Benefit Analysis; Hep G2 Cells; Humans; Mice; Pioglitazone; RNA-Seq; Transcriptome; Troglitazone | 2020 |